Regulation of glioma cell invasion by 3q26 gene products PIK3CA, SOX2 and OPA1.
Cell Line, Tumor
Cell Movement
/ genetics
Cell Proliferation
/ genetics
Chromosomes, Human, Pair 3
Class I Phosphatidylinositol 3-Kinases
/ genetics
DNA Copy Number Variations
GTP Phosphohydrolases
/ genetics
Glioma
/ genetics
HEK293 Cells
Humans
Necrosis
/ genetics
Neoplasm Invasiveness
Neoplasm Recurrence, Local
/ genetics
Phosphatidylinositol 3-Kinases
/ genetics
Phosphorylation
Proto-Oncogene Proteins c-akt
/ genetics
SOXB1 Transcription Factors
/ genetics
Signal Transduction
3q26
Glioma
cell invasion
neuroimaging
tumor necrosis
Journal
Brain pathology (Zurich, Switzerland)
ISSN: 1750-3639
Titre abrégé: Brain Pathol
Pays: Switzerland
ID NLM: 9216781
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
28
03
2018
revised:
17
10
2018
accepted:
22
10
2018
pubmed:
8
11
2018
medline:
8
1
2020
entrez:
8
11
2018
Statut:
ppublish
Résumé
Diffuse gliomas progress by invading neighboring brain tissue to promote postoperative relapse. Transcription factor SOX2 is highly expressed in invasive gliomas and maps to chromosome region 3q26 together with the genes for PI3K/AKT signaling activator PIK3CA and effector molecules of mitochondria fusion and cell invasion, MFN1 and OPA1. Gene copy number analysis at 3q26 from 129 glioma patient biopsies revealed mutually exclusive SOX2 amplifications (26%) and OPA1 losses (19%). Both forced SOX2 expression and OPA1 inactivation increased LN319 glioma cell invasion in vitro and promoted cell dispersion in vivo in xenotransplanted D. rerio embryos. While PI3 kinase activity sustained SOX2 expression, pharmacological PI3K/AKT pathway inhibition decreased invasion and resulted in SOX2 nucleus-to-cytoplasm translocation in an mTORC1-independent manner. Chromatin immunoprecipitation and luciferase reporter gene assays together demonstrated that SOX2 trans-activates PIK3CA and OPA1. Thus, SOX2 activates PI3K/AKT signaling in a positive feedback loop, while OPA1 deletion is interpreted to counteract OPA1 trans-activation. Remarkably, neuroimaging of human gliomas with high SOX2 or low OPA1 genomic imbalances revealed significantly larger necrotic tumor zone volumes, corresponding to higher invasive capacities of tumors, while autologous necrotic cells are capable of inducing higher invasion in SOX2 overexpressing or OPA1 knocked-down relative to parental LN319. We thus propose necrosis volume as a surrogate marker for the assessment of glioma invasive potential. Whereas glioma invasion is activated by a PI3K/AKT-SOX2 loop, it is reduced by a cryptic invasion suppressor SOX2-OPA1 pathway. Thus, PI3K/AKT-SOX2 and mitochondria fission represent connected signaling networks regulating glioma invasion.
Identifiants
pubmed: 30403311
doi: 10.1111/bpa.12670
pmc: PMC8028334
doi:
Substances chimiques
SOX2 protein, human
0
SOXB1 Transcription Factors
0
Class I Phosphatidylinositol 3-Kinases
EC 2.7.1.137
PIK3CA protein, human
EC 2.7.1.137
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
GTP Phosphohydrolases
EC 3.6.1.-
OPA1 protein, human
EC 3.6.1.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
336-350Informations de copyright
© 2018 International Society of Neuropathology.
Références
Oncotarget. 2015 Dec 22;6(41):43540-56
pubmed: 26498353
Cancer Lett. 2015 Jun 28;362(1):1-7
pubmed: 25796440
Cell Adh Migr. 2015;9(3):233-46
pubmed: 25482613
Stem Cells. 2009 Jan;27(1):40-8
pubmed: 18948646
Nat Rev Neurosci. 2014 Jul;15(7):455-65
pubmed: 24946761
J Exp Med. 2006 Dec 25;203(13):2879-86
pubmed: 17145957
Nat Genet. 2000 Oct;26(2):207-10
pubmed: 11017079
Sci Rep. 2016 Apr 14;6:24552
pubmed: 27076368
Oncol Rep. 2017 Nov;38(5):3167-3176
pubmed: 28901470
Nat Genet. 2008 May;40(5):499-507
pubmed: 18443585
Proc Natl Acad Sci U S A. 2016 Feb 2;113(5):1381-6
pubmed: 26787912
Nature. 2008 Oct 23;455(7216):1061-8
pubmed: 18772890
Mol Biol Cell. 2009 Aug;20(15):3525-32
pubmed: 19477917
J Neurosurg. 1993 Oct;79(4):533-6
pubmed: 8410222
Neurosurgery. 2002 Jul;51(1):2-12; discussion 12-3
pubmed: 12182418
J Neurol Psychiatry. 1940 Apr;3(2):147-77
pubmed: 21610973
Endocrinology. 2013 Apr;154(4):1540-52
pubmed: 23425966
Sci Rep. 2016 Mar 04;6:22455
pubmed: 26940200
Cancer Med. 2014 Aug;3(4):812-24
pubmed: 24810477
PLoS One. 2011;6(11):e26740
pubmed: 22069467
Biophys J. 2013 May 7;104(9):2077-88
pubmed: 23663851
J Neurooncol. 1996 Jan;27(1):65-73
pubmed: 8699228
Cell. 2011 Nov 23;147(5):992-1009
pubmed: 22118458
PLoS One. 2015 Mar 30;10(3):e0122308
pubmed: 25822260
Tumour Biol. 2014 Aug;35(8):7965-73
pubmed: 24833089
Cancer Lett. 2013 Aug 19;336(2):379-89
pubmed: 23545177
Science. 2004 Apr 23;304(5670):554
pubmed: 15016963
Cancer Res. 2009 Jan 15;69(2):458-65
pubmed: 19147558
Cell. 2014 Apr 24;157(3):580-94
pubmed: 24726434
Cancer Res. 2008 Aug 1;68(15):6084-91
pubmed: 18676830
Neuro Oncol. 2015 Nov;17(11):1525-37
pubmed: 26203066
Oncogene. 2011 Aug 4;30(31):3454-67
pubmed: 21383690
PLoS One. 2013;8(2):e56324
pubmed: 23424657
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Int J Mol Sci. 2015 Sep 08;16(9):21643-57
pubmed: 26370982
J Neurosurg. 2001 Sep;95(3):480-8
pubmed: 11565871
Mol Cell. 2017 Sep 21;67(6):922-935.e5
pubmed: 28918902
Ann N Y Acad Sci. 2012 Aug;1266:124-37
pubmed: 22901264
Brain Pathol. 1999 Jul;9(3):469-79
pubmed: 10416987
Cell Stem Cell. 2009 Nov 6;5(5):504-14
pubmed: 19896441
J Neurooncol. 2001 Jun;53(2):177-85
pubmed: 11716069